



11-14-05

JFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97 (c))

Docket No.

015/03937

In Re Application of:

Tami HAREL et al.

Application No.	Filing Date	Examiner	Customer No.	Art Unit	Confirmation No.
10/804,560	March 18, 2004	REIDEL, J.L	44909	3762	7075

Title:

BLOOD GLUCOSE LEVEL CONTROL

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97 (c))

Docket No.

015/03937

In Re Application of:

Tami HAREL et al.

Application No.

10/804,560

Filing Date

March 18, 2004

Examiner

REIDEL, J.L

Customer No.

44909

Art Unit

3762

Confirmation No.

7075

Title:

BLOOD GLUCOSE LEVEL CONTROL

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 03-3419 as described below.
- ☐ Charge the amount of \$00.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date) _____

Signature _____

Typed or Printed Name of Person Signing Certificate _____

Certificate of Mailing by First Class Mail


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date) _____

Signature of Person Mailing Correspondence _____

Typed or Printed Name of Person Signing Certificate _____

*This certificate may only be used if paying by deposit account.


Maier Fenster, Reg. No. 41,016

William H. Dippert, Esq.
Wolf, Block, Schorr & Solis-Cohen LLP
250 Park Avenue
New York, New York 10177
Tel: (212) 986 1116

NOV 2
Date: ~~October 31~~, 2005



015/03937

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Tami HAREL et al.

Serial No : 10/804,560

Group Art Unit: 3762

Filed : March 18, 2004

Examiner: Reidel, J.L

For : Blood Glucose Level Control

THIRD SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Hon. Commissioner of Patents and Trademarks

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Applicants respectfully direct the attention of the Examiner to art cited with respect to U.S. Application No. 10/804,560, which is a continuation-in-part under 35 U.S.C. §111(a) of PCT Application No. PCT/IL03/00736, which is a continuation-in-part under 35 U.S.C. §111(a) of U.S. Application No. 10/237,263, which is a continuation-in-part under 35 U.S.C. §111(a) of PCT Application No. PCT/IL00/00566. This application is also a continuation-in-part under 35 U.S.C. §111(a) of PCT Application No. PCT/IL00/00132, now U.S. Application No. 09/914,889.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP §2001.06, MPEP §1893.03(e) and MPEP §1893.03(g) and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is an Equivalent to Form PTO-1449 listing the cited art. Also attached are copies¹ of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

¹ To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated there between; if no such English language equivalent is cited then none is known to the undersigned.

Copies of items 1-8 are not attached, as the USPTO waived the requirement under 37 CFR 1.98(a)(2)(i) for submitting copies of US patents and US patent application publications in all U.S. applications filed after June 30, 2003. See MPEP 609 III A(2).

In accordance with MPEP §609 it is requested that each document cited [including any mentioned in Applicants' specification which is not repeated on the attached (or prior) PTO-1449 form(s) or equivalent(s) thereof] be given thorough consideration and be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form or its equivalent, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 C.F.R. §1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 C.F.R. §1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,
Tami HAREL et al.



Maier FENSTER,
Registration No. 41,016

Nov 2
~~October 31~~, 2005

William H. Dippert, Esq.
Wolf, Block, Schorr & Solis-Cohen LLP
250 Park Avenue
New York, NY 10177
Tel: (212) 986-1116



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 015/03937	SERIAL NO. 10/804,560
	APPLICANT(S) Tami HAREL et al.	
	FILING March 18, 2004	GROUP 3762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate
	1.	5,188,104	23 Feb '93	WERNICKE et al.			
	2.	5,690,691	25 Nov '97	CHEN et al.			
	3.	5,861,014	19 Jan '99	FAMILONI			
	4.	6,083,249	04 Jul '00	FAMILONI			
	5.	6,243,607	05 Jun '01	MINTCHEV et al.			
	6.	6,381,495	30 Apr '02	JENKIS			
	7.	6,449,511	10 Sep '02	MINTCHEV et al.			
	8.	6,658,297	02 Dec '03	LOEB			

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-A820
(also form PTO-1449)

Patent and Trademark Office*U.S. DEPARTMENT OF COMMERCE



PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Express Mail Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail under 37 CFR 1.10 on the date indicated below and is addressed to:

Mail Stop: AMENDMENT
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 9, 2005
Date

EV793688456US

Express Mail Label

Geraldine Gress

Wolf, Block, Schorr and Solis-Cohen LLP
250 Park Avenue
10th Floor
New York, New York 10177-0030
Telephone: 212.986.1116; Facsimile: 212.986.0604

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Applicant: Tami Harel et al.
Serial No: 10/804,560
Filing Date: March 18, 2004
For: Blood Glucose Level Control
Enclosures: (1) Transmittal of IDS (3 pages);
(2) Third Supplementary Information Disclosure Statement (2 pages);
(3) IDS Citation (1 page);
(4) Acknowledgement Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.